GENESIS Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

GENESIS Pharma is a leading regional commercial partner in Central and Eastern Europe, dedicated to bringing innovative biopharmaceuticals and orphan drugs to patients. With nearly three decades of experience, the company has built a strong network of subsidiaries across the CEE region and strategic alliances with global biopharma innovators. Its business model centers on in-licensing and commercializing advanced therapies for chronic and rare diseases, making it a critical access channel for groundbreaking treatments in its markets.

NeurologyGenetic DiseasesOncologyHematologyRheumatologyDermatologyNephrologyGastroenterologyCardiology

Technology Platform

Specialized regional commercial platform for CEE markets, encompassing regulatory affairs, market access, pharmacovigilance, marketing, sales, and distribution for innovative biopharmaceuticals and orphan drugs.

Opportunities

The growing global pipeline of innovative biologics and orphan drugs creates a steady stream of potential partnership opportunities.

Additionally, healthcare modernization and increased funding for specialty medicines in CEE countries are expanding the addressable market for its portfolio.

Risk Factors

Revenue is dependent on the success of partnered products and the renewal of licensing agreements.

The company also faces significant regulatory and reimbursement uncertainty across the diverse and politically complex healthcare systems of Central and Eastern Europe.

Competitive Landscape

GENESIS Pharma competes with other regional commercialization partners, the local affiliates of global pharmaceutical giants, and potentially direct market entry by its partners. Its deep, long-standing regional integration and specialized focus on complex therapies are key differentiators.

More companies in Europe - Other →